<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>TB R&#38;D Matters Blog &#187; South Africa</title>
	<atom:link href="http://www.newtbdrugs.org/blog/tag/south-africa/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.newtbdrugs.org/blog</link>
	<description>Working Towards a Faster Cure for Tuberculosis</description>
	<lastBuildDate>Wed, 15 May 2013 17:30:21 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>TB R&amp;D Weekly Update:  TB Vaccine Efficacy Trial Yields Key Insights and Poor Results</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-tb-vaccine-efficacy-trial-yields-key-insights-and-poor-results/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-tb-vaccine-efficacy-trial-yields-key-insights-and-poor-results/#comments</comments>
		<pubDate>Mon, 04 Feb 2013 21:10:42 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[TB News]]></category>
		<category><![CDATA[TB Pediatrics]]></category>
		<category><![CDATA[TB Prevention and Control Strategies]]></category>
		<category><![CDATA[aeras]]></category>
		<category><![CDATA[children]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[mva85a]]></category>
		<category><![CDATA[oxford]]></category>
		<category><![CDATA[pediatric]]></category>
		<category><![CDATA[phase II]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[South Africa]]></category>
		<category><![CDATA[tbvi]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=4243</guid>
		<description><![CDATA[The results of the first TB vaccine efficacy trial in over 90 years was released today showing that the vaccine candidate MVA85A when given as a booster did not provide added protection to infants who had already received BCG.  The trial adds scientific value to the field and enhances the field's understanding and ability in conducting large-scale TB vaccine trials.  Additional links to TB R&#038;D news are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-tb-vaccine-efficacy-trial-yields-key-insights-and-poor-results/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Integrating TB and HIV Services at the Community Level</title>
		<link>http://www.newtbdrugs.org/blog/integrating-tb-and-hiv-services-at-the-community-level/</link>
		<comments>http://www.newtbdrugs.org/blog/integrating-tb-and-hiv-services-at-the-community-level/#comments</comments>
		<pubDate>Tue, 19 Jun 2012 19:45:45 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Faces of TB]]></category>
		<category><![CDATA[TB R&D Spotlight Interviews]]></category>
		<category><![CDATA[Video]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[collaborations]]></category>
		<category><![CDATA[community]]></category>
		<category><![CDATA[community health worker]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[South Africa]]></category>
		<category><![CDATA[stigma]]></category>
		<category><![CDATA[training]]></category>
		<category><![CDATA[voices]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3978</guid>
		<description><![CDATA[This week we highlight an interview with Jeannine Uwimana, a public health specialist from the University of the Western Cape and TB/HIV Care Association in South Africa.  She discusses her work in developing models for community-based programs to enhance TB and HIV collaborative activities.  ]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/integrating-tb-and-hiv-services-at-the-community-level/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Community Engagement through Drama</title>
		<link>http://www.newtbdrugs.org/blog/community-engagement-through-drama/</link>
		<comments>http://www.newtbdrugs.org/blog/community-engagement-through-drama/#comments</comments>
		<pubDate>Tue, 17 Apr 2012 17:16:46 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Faces of TB]]></category>
		<category><![CDATA[TB Patient Perspective]]></category>
		<category><![CDATA[TB R&D Spotlight Interviews]]></category>
		<category><![CDATA[TB Stigma]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[WGND Podcast Series]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[community]]></category>
		<category><![CDATA[community engagement]]></category>
		<category><![CDATA[education]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[mdr]]></category>
		<category><![CDATA[podcast]]></category>
		<category><![CDATA[social impact]]></category>
		<category><![CDATA[South Africa]]></category>
		<category><![CDATA[tb/hiv]]></category>
		<category><![CDATA[voices]]></category>
		<category><![CDATA[youth empowerment]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3729</guid>
		<description><![CDATA[Dr. Gill Black is the co-founder and Director of Health and Welfare at The Sustainable Livelihoods Foundation (SLF).  In this inteview, we discuss with Dr. Black one of SLF's groundbreaking projects that uses drama to engage local communities around issues related to TB and HIV/AIDS.  ]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/community-engagement-through-drama/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  Results from Preventative Therapy Trial in SA Miners</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-results-from-preventative-therapy-trial-in-sa-miners/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-results-from-preventative-therapy-trial-in-sa-miners/#comments</comments>
		<pubDate>Fri, 09 Mar 2012 16:54:53 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[TB News]]></category>
		<category><![CDATA[TB Prevention and Control Strategies]]></category>
		<category><![CDATA[TB Treatment]]></category>
		<category><![CDATA[aurum]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[croi]]></category>
		<category><![CDATA[isoniazid]]></category>
		<category><![CDATA[london school]]></category>
		<category><![CDATA[miners]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[preventative therapy]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[South Africa]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3555</guid>
		<description><![CDATA[At the 19th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, results on the Thibela TB preventative therapy trial in South Africa gold miners  was presented with mixed outcomes.  Additional links to TB R&#038;D news are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-results-from-preventative-therapy-trial-in-sa-miners/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>News from the 21st Stop TB Partnership Coordinating Board Meeting, Bangkok</title>
		<link>http://www.newtbdrugs.org/blog/news-from-the-21st-stop-tb-partnership-coordinating-board-meeting-bangkok/</link>
		<comments>http://www.newtbdrugs.org/blog/news-from-the-21st-stop-tb-partnership-coordinating-board-meeting-bangkok/#comments</comments>
		<pubDate>Tue, 31 Jan 2012 19:37:16 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Action]]></category>
		<category><![CDATA[Announcements]]></category>
		<category><![CDATA[Events]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[South Africa]]></category>
		<category><![CDATA[stop tb]]></category>
		<category><![CDATA[TAG]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3455</guid>
		<description><![CDATA[he 21st Stop TB Partnership Coordinating Board retreat and meeting officially started in Bangkok, Thailand, on Sunday, January 29th with the official opening ceremony held yesterday January 30th. Included are some exciting news from the meeting courtesy of Mark Harrington, Executive Director of the Treatment Action Group (TAG). ]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/news-from-the-21st-stop-tb-partnership-coordinating-board-meeting-bangkok/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
		</item>
		<item>
		<title>Kick TB Campaign:  Scoring Big in South Africa and Beyond</title>
		<link>http://www.newtbdrugs.org/blog/kick-tb-campaign-scoring-big-in-south-africa-and-beyond/</link>
		<comments>http://www.newtbdrugs.org/blog/kick-tb-campaign-scoring-big-in-south-africa-and-beyond/#comments</comments>
		<pubDate>Wed, 18 Jan 2012 19:22:32 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Faces of TB]]></category>
		<category><![CDATA[TB Prevention and Control Strategies]]></category>
		<category><![CDATA[Video]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[children]]></category>
		<category><![CDATA[community]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[South Africa]]></category>
		<category><![CDATA[voices]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3403</guid>
		<description><![CDATA[The Kick TB Campaign is a unique project that uses the World's most popular sport to educate and engage young people in the effort to stop the spread of tuberculosis (TB).  ]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/kick-tb-campaign-scoring-big-in-south-africa-and-beyond/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  Early bactericidal activity of OPC-67683</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-early-bactericidal-activity-of-opc-67683/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-early-bactericidal-activity-of-opc-67683/#comments</comments>
		<pubDate>Tue, 12 Jul 2011 20:31:44 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[mdr]]></category>
		<category><![CDATA[otsuka]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[South Africa]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=2928</guid>
		<description><![CDATA[This week, we review a recent article published in the July issue of IJTLD on the TB drug candidate OPC-67683 whose new generic name is delamanid.  Diacon, et al., present data showing that delamanid is safe, well-tolerated with significant early bactericidal activity.  Links to additional TB R&#038;D news is included.  ]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-early-bactericidal-activity-of-opc-67683/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Interview with Dr. Mark Cotton &#8211; Part Two</title>
		<link>http://www.newtbdrugs.org/blog/interview-with-dr-mark-cotton-part-two/</link>
		<comments>http://www.newtbdrugs.org/blog/interview-with-dr-mark-cotton-part-two/#comments</comments>
		<pubDate>Thu, 12 May 2011 11:00:46 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[TB Pediatrics]]></category>
		<category><![CDATA[TB Treatment]]></category>
		<category><![CDATA[Video]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[pediatric]]></category>
		<category><![CDATA[South Africa]]></category>
		<category><![CDATA[tb/hiv]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[voices]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=2566</guid>
		<description><![CDATA[Dr. Mark Cotton is Director of Children's Infectious Diseases Clinical  Research Unit (KID-CRU) at University of Stellenbosch in Cape Town,  South Africa. Pediatric TB has emerged as a broad priority only in more recent years, though the University of Stellenbosch / Tygerberg Hospital team has been focusing on it for more than 20 years.  This is part two of our interview with him.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/interview-with-dr-mark-cotton-part-two/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  Podcast Interview with Dr. Bernard Fourie</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-dr-bernard-fourie/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-dr-bernard-fourie/#comments</comments>
		<pubDate>Wed, 11 May 2011 20:01:55 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[WGND Podcast Series]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[South Africa]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=2622</guid>
		<description><![CDATA[The WGND had the opportunity to interview Dr. Bernard Fourie who is head of Medicine in Need-South Africa (MEND-SA).retoria, South Africa.  In the interview,  we discuss the ongoing projects at the Drug Research Laboratory at MEND-SA, a research and development center with the mission to developing and applying innovative approaches to the formulation and optimization of existing drugs for the treatment of tuberculosis.  Additional links to TB R&#038;D News are included.  ]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-dr-bernard-fourie/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Interview with Dr. Mark Cotton &#8211; Part One</title>
		<link>http://www.newtbdrugs.org/blog/interview-with-dr-mark-cotton-part-one/</link>
		<comments>http://www.newtbdrugs.org/blog/interview-with-dr-mark-cotton-part-one/#comments</comments>
		<pubDate>Thu, 28 Apr 2011 11:00:03 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[TB Pediatrics]]></category>
		<category><![CDATA[TB Treatment]]></category>
		<category><![CDATA[Video]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[pediatric]]></category>
		<category><![CDATA[South Africa]]></category>
		<category><![CDATA[tb/hiv]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[voices]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=2559</guid>
		<description><![CDATA[Dr. Mark Cotton is Director of Children's Infectious Diseases Clinical Research Unit (KID-CRU) at University of Stellenbosch in Cape Town, South Africa. Pediatric TB has emerged as a broad priority only in more recent years, though the University of Stellenbosch / Tygerberg Hospital team has been focusing on it for more than 20 years. ]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/interview-with-dr-mark-cotton-part-one/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
